DE60319073D1 - Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren - Google Patents
Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitorenInfo
- Publication number
- DE60319073D1 DE60319073D1 DE60319073T DE60319073T DE60319073D1 DE 60319073 D1 DE60319073 D1 DE 60319073D1 DE 60319073 T DE60319073 T DE 60319073T DE 60319073 T DE60319073 T DE 60319073T DE 60319073 D1 DE60319073 D1 DE 60319073D1
- Authority
- DE
- Germany
- Prior art keywords
- map
- kinase inhibitors
- activated protein
- nanoparticle compositions
- mitogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 230000002297 mitogenic effect Effects 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36552402P | 2002-03-20 | 2002-03-20 | |
| US365524P | 2002-03-20 | ||
| PCT/US2003/008547 WO2003080024A2 (en) | 2002-03-20 | 2003-03-20 | Nanoparticulate compositions of map kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60319073D1 true DE60319073D1 (de) | 2008-03-27 |
| DE60319073T2 DE60319073T2 (de) | 2009-02-05 |
Family
ID=28454669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60319073T Expired - Lifetime DE60319073T2 (de) | 2002-03-20 | 2003-03-20 | Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030181411A1 (de) |
| EP (1) | EP1490025B1 (de) |
| JP (2) | JP4611641B2 (de) |
| AT (1) | ATE385777T1 (de) |
| AU (1) | AU2003230692A1 (de) |
| CA (1) | CA2479737C (de) |
| DE (1) | DE60319073T2 (de) |
| ES (1) | ES2302925T3 (de) |
| WO (1) | WO2003080024A2 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| US20020119237A1 (en) * | 2000-12-22 | 2002-08-29 | Hevey Maurice O. | Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis |
| EP1471887B1 (de) | 2002-02-04 | 2010-04-21 | Elan Pharma International Ltd. | Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator |
| US20040225077A1 (en) | 2002-12-30 | 2004-11-11 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7279576B2 (en) * | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US20080045706A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
| US20040248982A1 (en) * | 2003-06-09 | 2004-12-09 | Dyer Gordon Wayne | Use of compounds for the inhibition of proteins and UV protection |
| DE602004018150D1 (de) * | 2003-08-08 | 2009-01-15 | Elan Pharma Int Ltd | Neue metaxalon-zusammensetzungen |
| JP4787165B2 (ja) * | 2003-11-05 | 2011-10-05 | エラン ファーマ インターナショナル，リミティド | 表面安定剤としてペプチドを有するナノ粒子組成物 |
| US7109163B2 (en) * | 2004-01-30 | 2006-09-19 | Ethicon, Inc. | Hemostatic compositions and devices |
| US20060025485A1 (en) * | 2004-07-01 | 2006-02-02 | Kyle Holen | Hydroxybenazamide compounds for treatment of cancer |
| JP2007223903A (ja) * | 2004-07-09 | 2007-09-06 | Takeda Chem Ind Ltd | 新規な固体分散体およびその製造方法 |
| WO2006110811A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
| US20110064803A1 (en) * | 2005-05-10 | 2011-03-17 | Elan Pharma International Limited. | Nanoparticulate and controlled release compositions comprising vitamin k2 |
| EP1888037A2 (de) * | 2005-05-10 | 2008-02-20 | Elan Pharma International Limited | Clopidogrel-nanopartikelformulierungen |
| US20070042049A1 (en) * | 2005-06-03 | 2007-02-22 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
| WO2006133046A2 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate imatinib mesylate formulations |
| WO2007053197A2 (en) * | 2005-06-03 | 2007-05-10 | Elan Pharma International, Limited | Nanoparticulate acetaminophen formulations |
| DE112006001606T5 (de) | 2005-06-08 | 2009-07-09 | Elan Pharma International Ltd., Athlone | Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen |
| JP2008543766A (ja) * | 2005-06-09 | 2008-12-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子エバスチン製剤 |
| BRPI0611626A2 (pt) * | 2005-06-13 | 2010-09-21 | Elan Pharma Int Ltd | formulações da combinação de nanopartìculas de clopidogrel e aspirina |
| US20100221327A1 (en) * | 2005-06-15 | 2010-09-02 | Elan Pharma International Limited | Nanoparticulate azelnidipine formulations |
| US20070015719A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
| US20070104792A1 (en) * | 2005-09-13 | 2007-05-10 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
| JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
| JP2009538927A (ja) | 2006-05-30 | 2009-11-12 | エラン ファーマ インターナショナル，リミティド | ナノ粒子状のポサコナゾール製剤 |
| KR20090018864A (ko) * | 2006-06-13 | 2009-02-23 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 키나제 억제제 제제 |
| US20080317843A1 (en) * | 2006-07-12 | 2008-12-25 | Elan Corporation Plc | Nanoparticulate formulations of modafinil |
| US8309138B2 (en) * | 2007-02-16 | 2012-11-13 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| JP2010526822A (ja) * | 2007-05-07 | 2010-08-05 | クエスター ファーマシューティカルズ，インク． | ベンゾジアゼピン類の経鼻投与 |
| US8530463B2 (en) * | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| WO2009117401A2 (en) * | 2008-03-21 | 2009-09-24 | Elan Pharama International Limited | Compositions for site-specific delivery of imatinib and methods of use |
| WO2009121039A2 (en) | 2008-03-28 | 2009-10-01 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| US8110608B2 (en) | 2008-06-05 | 2012-02-07 | Ecolab Usa Inc. | Solid form sodium lauryl sulfate (SLS) pesticide composition |
| EP2172193A1 (de) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Verbesserte Nanopartikel-Zusammensetzungen schlecht löslicher Verbindungen |
| EP3167875A1 (de) | 2009-05-27 | 2017-05-17 | Alkermes Pharma Ireland Limited | Reduktion von flockenartiger aggregation in nanoteilchenförmigen meloxicamzusammensetzungen |
| TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| US9889098B2 (en) | 2009-10-22 | 2018-02-13 | Vizuri Health Sciences Llc | Methods of making and using compositions comprising flavonoids |
| US8968757B2 (en) | 2010-10-12 | 2015-03-03 | Ecolab Usa Inc. | Highly wettable, water dispersible, granules including two pesticides |
| CN103796656A (zh) | 2011-06-14 | 2014-05-14 | 哈尔生物药投资有限责任公司 | 苯二氮卓的投与 |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| EP3368040B1 (de) * | 2015-10-26 | 2022-08-17 | Eip Pharma, LLC | Verfahren und zusammensetzungen zur erholung nach einem schlaganfall |
| WO2019056003A1 (en) | 2017-09-18 | 2019-03-21 | Eip Pharma, Llc | CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745) |
| JP2020152673A (ja) | 2019-03-20 | 2020-09-24 | 株式会社リコー | ナノ粒子及びナノ粒子の製造方法、並びに医薬 |
| KR102723100B1 (ko) * | 2019-06-26 | 2024-10-28 | 가부시키가이샤 리코 | 의약 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| JP4107693B2 (ja) * | 1996-02-09 | 2008-06-25 | 保土谷化学工業株式会社 | 固体粒子水性懸濁液の製造方法 |
| US6361938B1 (en) * | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| WO2000012124A1 (en) * | 1998-09-01 | 2000-03-09 | Elan Corporation, Plc | Oral vaccine compositions |
| EP2266542A3 (de) * | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Nanopartikelformulierungen mit kontrollierter Wirkstofffreisetzung |
| EP1261334A1 (de) * | 1998-10-20 | 2002-12-04 | Omeros Corporation | Spüllösung enthaltend mapk hemmern und deren verwendung zur behandlung von schmerz und entzündung |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| WO2001019322A2 (en) * | 1999-09-17 | 2001-03-22 | Smithkline Beecham Corporation | Use of csaids in rhinovirus infection |
-
2003
- 2003-03-20 AT AT03723782T patent/ATE385777T1/de not_active IP Right Cessation
- 2003-03-20 DE DE60319073T patent/DE60319073T2/de not_active Expired - Lifetime
- 2003-03-20 US US10/392,303 patent/US20030181411A1/en not_active Abandoned
- 2003-03-20 CA CA2479737A patent/CA2479737C/en not_active Expired - Fee Related
- 2003-03-20 WO PCT/US2003/008547 patent/WO2003080024A2/en active IP Right Grant
- 2003-03-20 EP EP03723782A patent/EP1490025B1/de not_active Expired - Lifetime
- 2003-03-20 JP JP2003577854A patent/JP4611641B2/ja not_active Expired - Fee Related
- 2003-03-20 AU AU2003230692A patent/AU2003230692A1/en not_active Abandoned
- 2003-03-20 ES ES03723782T patent/ES2302925T3/es not_active Expired - Lifetime
-
2010
- 2010-07-28 JP JP2010168818A patent/JP2010280685A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1490025A2 (de) | 2004-12-29 |
| JP2005526785A (ja) | 2005-09-08 |
| EP1490025B1 (de) | 2008-02-13 |
| JP4611641B2 (ja) | 2011-01-12 |
| AU2003230692A8 (en) | 2003-10-08 |
| ES2302925T3 (es) | 2008-08-01 |
| JP2010280685A (ja) | 2010-12-16 |
| DE60319073T2 (de) | 2009-02-05 |
| CA2479737C (en) | 2011-05-24 |
| WO2003080024A3 (en) | 2004-04-08 |
| AU2003230692A1 (en) | 2003-10-08 |
| ATE385777T1 (de) | 2008-03-15 |
| WO2003080024A2 (en) | 2003-10-02 |
| CA2479737A1 (en) | 2003-10-02 |
| US20030181411A1 (en) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60319073D1 (de) | Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren | |
| ATE343376T1 (de) | Nanopartikelzusammensetzungen von angiogeneseinhibitoren | |
| CY1107810T1 (el) | Συνθεσεις οι οποιες εχουν ενα συνδυασμο χαρακτηριστικων αμεσης απελευθερωσης και ελεγχομενης απελευθερωσης | |
| ATE387186T1 (de) | Neue zusammensetzungen von sildenafil-freier base | |
| DE602004021107D1 (de) | Meloxican-formulierungen in nanoteilchenform | |
| ATE457718T1 (de) | Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator | |
| SG161203A1 (en) | Nanoparticulate tacrolimus formulations | |
| CY1106420T1 (el) | Νανοσωματιδιακα σκευασματα ινσουλινης | |
| ATE419835T1 (de) | Nystatin-nanopartikelzusammensetzungen | |
| EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
| WO2005005462A3 (en) | Blys antagonists and uses thereof | |
| WO2001075178A3 (en) | Methods for identifying peptide aptamers capable of altering a cell phenotype | |
| ATE353320T1 (de) | Tricyclische proteinkinasehemmer | |
| DE60205776T2 (de) | Indolinon-derivative als protein-kinasehemmer | |
| WO2004030622A3 (en) | Method of isolation and self-assembly of small protein particles from blood and other biological materials | |
| WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
| SG162811A1 (en) | Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds | |
| NO20006026L (no) | Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC | |
| MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
| BR0208961A (pt) | Composição farmacêutica demonstrando atividade anti-tumor, método para fabricar a mesma, e uso de uma tolueno sulfonamida | |
| DE602004013937D1 (de) | Kombinationspräparate zur verhinderung von schlagand einen atii antagonisten enthalten | |
| WO2005037231A3 (en) | Methods of detecting and treating facioscapulohumeral muscular dystrophy | |
| WO2003014152A3 (en) | Phosphatidylinositol 5-phosphate-binding proteins | |
| AU2003276850A1 (en) | Compositions and methods used for identifying factors required for the agglomeration of proteins | |
| EP1570235A3 (de) | Zusammensetzungen und verfahren zur identifizierung von faktoren, die für die agglomeration von proteinen erforderlich sind |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |